Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance.

Cisplatin is a potent cytotoxic agent that functions as a bivalent electrophile, forming both interstrand and intrastrand DNA cross-links. Cisplatin-mediated DNA damage results in cell cycle arrest and initiation of apoptotic cell death. Increased cellular glutathione concentrations have been closely correlated with cisplatin resistance but do not reduce the extent of cisplatin-DNA adduct formation. One hypothesis to explain the ability of glutathione to inhibit cisplatin cytotoxicity is that glutathione, through its antioxidant function, plays a role in apoptotic regulatory pathways. We tested this hypothesis using MCF-7 breast cancer cells transfected with the apoptotic inhibitor Bcl-2. Bcl-2 overexpression in MCF-7 cells was associated with a nearly 3-fold increase in cellular glutathione levels and with increased resistance to cell death after cisplatin exposure. Treatment of MCF-7 lines with buthionine sulfoximine, an inhibitor of glutathione synthesis, normalized glutathione levels in Bcl-2 and control transfectants and completely abrogated Bcl-2-mediated cisplatin resistance without affecting Bcl-2 expression. Bcl-2 overexpression and up-regulation of glutathione were not associated with a change in either cisplatin-DNA adduct formation or repair over time. These results suggest that Bcl-2-mediated cisplatin resistance in MCF-7 cells is dependent on up-regulation of glutathione production, which contributes to cell survival by mechanisms independent of cisplatin inactivation or inhibition of DNA adduct formation. A similar dependence on glutathione for Bcl-2-mediated inhibition of cisplatin toxicity was confirmed in a second cell line, the lymphocytic precursor FL5.12. Taken together, these data suggest that apoptotic signaling after genotoxic exposure can be inhibited by the antioxidant activity of glutathione. Inhibition of glutathione synthesis or modulation of glutathione stores in tumors that overexpress Bcl-2 may comprise a novel anticancer strategy.

[1]  L. Ellerby,et al.  Effect of overexpression of BCL-2 on cellular oxidative damage, nitric oxide production, antioxidant defenses, and the proteasome. , 2001, Free radical biology & medicine.

[2]  B. Trump,et al.  BCL-2 is involved in preventing oxidant-induced cell death and in decreasing oxygen radical production , 2001, Redox report : communications in free radical research.

[3]  J. Essigmann,et al.  Mechanisms of resistance to cisplatin. , 2001, Mutation research.

[4]  Rachel L. Allen,et al.  Defying death after DNA damage , 2000, Nature.

[5]  D. Mustacich,et al.  The role of the redox protein thioredoxin in cell growth and cancer. , 2000, Free radical biology & medicine.

[6]  T. Matsumura,et al.  Regulation of Apoptosis Reduction in the Cisplatin-Resistant A431 Cell Line by Bcl-2 and CPP32 , 1999, Chemotherapy.

[7]  Matthew G. Vander Heiden,et al.  Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis? , 1999, Nature Cell Biology.

[8]  H. Miyake,et al.  Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2. , 1999, The Journal of urology.

[9]  B. Trock,et al.  Prognostic Value of p53, Glutathione S-Transferase π, and Thymidylate Synthase for Neoadjuvant Cisplatin-based Chemotherapy in Head and Neck Cancer , 1999 .

[10]  D. Voehringer.  BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. , 1999, Free radical biology & medicine.

[11]  T. Furukawa,et al.  Resistance to cisplatin. , 1999, Anti-cancer drug design.

[12]  R. Wood,et al.  Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours , 1999, Current Biology.

[13]  R. Stahel,et al.  Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. , 1998, British Journal of Cancer.

[14]  N. Chandel,et al.  Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Korsmeyer,et al.  Enhanced Oxidative Stress and Altered Antioxidants in Brains of Bcl‐2‐Deficient Mice , 1998, Journal of neurochemistry.

[16]  N. Chandel,et al.  Intracellular Signaling by Reactive Oxygen Species during Hypoxia in Cardiomyocytes* , 1998, The Journal of Biological Chemistry.

[17]  M. Anderson,et al.  Glutathione: an overview of biosynthesis and modulation. , 1998, Chemico-biological interactions.

[18]  B. Trock,et al.  Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer. , 1998, Chemico-biological interactions.

[19]  D. Voehringer,et al.  Bcl-2 expression causes redistribution of glutathione to the nucleus. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. Kroemer,et al.  The thiol crosslinking agent diamide overcomes the apoptosis-inhibitory effect of Bcl-2 by enforcing mitochondrial permeability transition , 1998, Oncogene.

[21]  H. Miyake,et al.  Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer , 1998, Oncogene.

[22]  G. Powis,et al.  Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. , 1997, Cancer research.

[23]  N. Kaplowitz,et al.  Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol‐treated rats: Effect of membrane physical properties and S‐adenosyl‐L‐methionine , 1997, Hepatology.

[24]  A. V. D. Van Der Zee,et al.  hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents , 1997, Oncogene.

[25]  N. Kaplowitz,et al.  GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. , 1997, The American journal of physiology.

[26]  G. Kroemer,et al.  Redox regulation of apoptosis: Impact of thiol oxidation status on mitochondrial function , 1997, European journal of immunology.

[27]  S. Aebi,et al.  The role of DNA mismatch repair in platinum drug resistance. , 1996, Cancer research.

[28]  E. Montgomery,et al.  Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  G. Núñez,et al.  Bax Can Antagonize Bcl-XL during Etoposide and Cisplatin-induced Cell Death Independently of Its Heterodimerization with Bcl-XL* , 1996, The Journal of Biological Chemistry.

[30]  P. Modrich,et al.  Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line* , 1996, The Journal of Biological Chemistry.

[31]  C. Boland,et al.  Loss of DNA mismatch repair in acquired resistance to cisplatin. , 1996, Cancer research.

[32]  S. Lippard,et al.  DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo. , 1995, Biochemistry.

[33]  N. Kaplowitz,et al.  Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: studies with isolated mitochondria and rat hepatocytes. , 1995, Molecular pharmacology.

[34]  Y. Tsujimoto,et al.  Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL , 1995, Nature.

[35]  M. Raff,et al.  Programmed cell death and Bcl-2 protection in very low oxygen , 1995, Nature.

[36]  J. Yu,et al.  Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. , 1994, The Journal of clinical investigation.

[37]  Z. Oltvai,et al.  Bcl-2 functions in an antioxidant pathway to prevent apoptosis , 1993, Cell.

[38]  S. Korsmeyer,et al.  Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair , 1993, Cell.

[39]  John Calvin Reed,et al.  Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. , 1993, Cancer research.

[40]  T. Ishikawa,et al.  Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. , 1993, The Journal of biological chemistry.

[41]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[42]  T. Ishikawa,et al.  The ATP-dependent glutathione S-conjugate export pump. , 1992, Trends in biochemical sciences.

[43]  V. Bohr,et al.  ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. , 1992, Journal of the National Cancer Institute.

[44]  J. Neter,et al.  Applied Linear Statistical Models (3rd ed.). , 1992 .

[45]  A. Meister,et al.  Inhibition of glutathione synthesis in the newborn rat: a model for endogenously produced oxidative stress. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[46]  V. Ling,et al.  Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum(II). , 1990, The Journal of biological chemistry.

[47]  B. Teicher,et al.  Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum , 1990, Molecular and Cellular Biochemistry.

[48]  C. Sorenson,et al.  Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. , 1990, Journal of the National Cancer Institute.

[49]  A. Meister.  Glutathione metabolism and its selective modification. , 1988, The Journal of biological chemistry.

[50]  R. Tarone,et al.  The measurement of cisplatin-DNA adduct levels in testicular cancer patients. , 1988, Carcinogenesis.

[51]  R. Tarone,et al.  Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[52]  A. Eastman.  Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes. , 1987, Chemico-biological interactions.

[53]  R. Ozols,et al.  Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. , 1986, The Journal of clinical investigation.

[54]  S. Lippard,et al.  In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. , 1985, Biochemistry.

[55]  A. Meister,et al.  Origin and turnover of mitochondrial glutathione. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[56]  P. Lohman,et al.  Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. , 1985, Biochemistry.

[57]  A. Eastman.  Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II). , 1983, Biochemistry.

[58]  V. Barnett,et al.  Applied Linear Statistical Models , 1975 .

[59]  F. Tietze.  Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. , 1969, Analytical biochemistry.

[60]  J. Doroshow,et al.  Effects of storage on the binding of carboplatin to plasma proteins , 2004, Cancer Chemotherapy and Pharmacology.

[61]  C. Rudin,et al.  Cisplatin Resistance Inhibition of Glutathione Synthesis Reverses Bcl-2-mediated Updated Version Cited Articles Citing Articles E-mail Alerts Inhibition of Glutathione Synthesis Reverses Bcl-2-mediated Cisplatin Resistance We Tested This Hypothesis Using Mcf-7 Breast Cancer Cells Transfected with th , 2022 .

[62]  K. Tew,et al.  Cellular thiols and reactive oxygen species in drug-induced apoptosis. , 2001, The Journal of pharmacology and experimental therapeutics.

[63]  Seth M. Cohen,et al.  Cisplatin: from DNA damage to cancer chemotherapy. , 2001, Progress in nucleic acid research and molecular biology.

[64]  P. Andrews,et al.  Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines , 2000, Cancer Chemotherapy and Pharmacology.

[65]  F. Gillardon,et al.  Alterations in cell death and cell cycle progression in the UV-irradiated epidermis of bcl-2-deficient mice , 1999, Cell Death and Differentiation.

[66]  P. Andrews,et al.  Glutathione content but not gamma glutamyl cysteine synthetase mRNA expression predicts cisplatin resistance in head and neck cancer cell lines , 1997, Cancer Chemotherapy and Pharmacology.

[67]  R. Ozols,et al.  Glutathione and drug resistance. , 1996, Cancer investigation.

[68]  A. Meister,et al.  Mitochondrial damage in muscle occurs after marked depletion of glutathione and is prevented by giving glutathione monoester. , 1989, Proceedings of the National Academy of Sciences of the United States of America.